< clinical trials / TransferAMI

Clinical Trial Name
"Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction- The TRANSFER-AMI trial"

Status: Enrolment complete.  
Patient follow up ongoing.

FDA Clinical Trial number:  
ClinicalTrials.gov ID# NCT00164190 -  MCT-69798

Brief description:  
Facilitated PCI is an emerging strategy which combines thrombolytic therapy and angioplasty to achieve the benefits of primary angioplasty without the excessive treatment delays. After administration of thrombolytic therapy, patients are transported for urgent cardiac catheterization, and PCI of the culprit artery is performed as required. Although there is observational non-randomized data to support the efficacy of this approach, a randomized trial is required to compare facilitated PCI with the standard of care (thrombolysis, with urgent transfer only for failed reperfusion and / or clinical deterioration). This large randomized trial has been planned to evaluate the safety and efficacy of this approach. All the randomized patients are followed up for 1 month, 6 month and 1 year after randomization.

Eligibility:  
Patients ³ 18 years old who present within 12 hours of symptom onset with more than 30 minutes of continuous symptoms of an acute myocardial infarction, with specific ECG findings.

Inclusion/exclusion criteria:
Patients ³ 18 years old who present within 12 hours of symptom onset with more than 30 minutes of continuous symptoms of an acute myocardial infarction,
with either:

i) ³ 2 mm ST-segment elevation in 2 or more contiguous anterior leads
ii)³ 1 mm ST-segment elevation in 2 or more contiguous inferior leads with either: